The association between the degree of HPV 16m and risk of being diagnosed with CIN 2+
| Cases vs. non-cases | ||||||
|---|---|---|---|---|---|---|
| Model 1a | Model 2b | Model 3c | ||||
| Risk factors | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
| Age, y | ||||||
| <23 | 1.00 | 0.21 | 1.00 | 0.15 | 1.00 | 0.14 |
| ≥23 | 1.43 (0.82–2.54) | 1.53 (0.86–2.74) | 1.54 (0.87–2.75) | |||
| Race | ||||||
| Caucasian American | 1.00 | 0.93 | 1.00 | 0.99 | 1.00 | 0.93 |
| African American | 1.03 (0.55–1.92) | 1.00 (0.53–1.88) | 0.97 (0.52–1.82) | |||
| Education | ||||||
| High school education or higher | 1.00 | 0.88 | 1.00 | 0.91 | 1.00 | 0.89 |
| Less than high school education | 1.05 (0.55–1.96) | 0.96 (0.50–1.81) | 1.05 (0.55–1.96) | |||
| Waist circumference, cm | ||||||
| ≤88 | 1.00 | 0.25 | 1.00 | 0.37 | 1.00 | 0.32 |
| >88 | 0.73 (0.41–1.26) | 0.78 (0.44–1.35) | 0.76 (0.43–1.31) | |||
| Smoking status | ||||||
| Never smoker | 1.00 | 0.23 | 1.00 | 0.22 | 1.00 | 0.24 |
| Ever smoker | 1.51 (0.76–3.05) | 1.54 (0.77–3.12) | 1.51 (0.76–3.05) | |||
| Lifetime number of sexual partners | ||||||
| ≤5 | 1.00 | 0.23 | 1.00 | 0.19 | 1.00 | 0.19 |
| >5 | 0.72 (0.41–1.24) | 0.69 (0.39–1.20) | 0.69 (0.40–1.20) | |||
| Use of oral/hormone contraceptive | ||||||
| Non-user | 1.00 | 0.99 | 1.00 | 0.92 | 1.00 | 0.90 |
| User | 1.00 (0.47–2.22) | 0.96 (0.45–2.14) | 1.05 (0.49–1.14) | |||
| Vitamin C, μg/mL | ||||||
| <15.13 | 1.00 | 0.42 | 1.00 | 0.76 | 1.00 | 0.53 |
| ≥15.13 | 1.25 (0.73–2.13) | 1.09 (0.63–1.88) | 1.19 (0.69–2.04) | |||
| Total carotene, μg% | ||||||
| <87.93 | 1.00 | 0.65 | 1.00 | 0.61 | 1.00 | 0.65 |
| ≥87.93 | 0.88 (0.50–1.53) | 0.86 (0.49–1.51) | 0.88 (0.50–1.54) | |||
| HPV 16m, % | ||||||
| Promoter site | ||||||
| <11 | 1.00 | 0.02 | — | |||
| ≥11 | 0.52 (0.30–0.88) | |||||
| Enhancer site | ||||||
| <10 | — | 1.00 | <0.01 | — | ||
| ≥10 | 0.37 (0.21–0.64) | |||||
| Promoter and enhancer site combined | ||||||
| <11 | — | — | 1.00 | <0.01 | ||
| ≥11 | 0.45 (0.26–0.78) | |||||